A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache
Latest Information Update: 01 Jun 2022
At a glance
- Drugs Galcanezumab (Primary)
- Indications Cluster headache
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CGAR
- Sponsors Eli Lilly and Company
- 27 May 2022 Results published in the Cephalalgia
- 12 Sep 2021 Results assessing effects of Galcanezumab in patients reported outcomes in cluster headache patients presented at The International Headache Congress-International headache Society with the European headache Federation joint congress 2021
- 22 Apr 2021 Results (n=39 from CGAL, NCT02397473 who enrolled in CGAR, NCT02797951) assessing consistency of effect with galcanezumab for episodic cluster headache (ECH) across multiple cluster periods,presented at the 73rd Annual Meeting of the American Academy of Neurology